Perseus Proteomics Inc. announced that there will be a delay in the end of the Phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among PV patients from the initial forecast of within the fiscal year ending March 31, 2024 to the end of June 2024. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to 6 patients suffering from PV, a disease characterized by excess increase in red blood cells (RBCs). The secondary purpose is to confirm the therapeutic effects.

The tests of the 4 patients have already ended and the Company has continued incremental administration of PPMX-T003 to the remaining 2 patients and follow-up observation. Due to the circumstances of the tests at the end of January, the observation period is to delay from the initial forecast. To be more concrete, administration to one patient was postponed due to circumstances and administration of the increased dosage to the other was decided.

This trial is estimated to finish at the end of June 2024.